How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
56
JAZZ Quote, Financials, Valuation and Earnings
Last price:
$166.78
Seasonality move
:
-0.2%
Day range:
$164.79 - $168.81
52-week range:
$95.49 - $182.99
Dividend yield:
0%
P/E ratio:
15.09x
P/S ratio:
2.46x
P/B ratio:
2.57x
Volume:
786.7K
Avg. volume:
1.1M
1-year change:
34.51%
Market cap:
$10.2B
Revenue:
$4.1B
EPS (TTM):
-$6.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.2B | $6.50 | 12.55% | 106.61% | $216.44 |
|
ALKS
Alkermes Plc
|
$380.4M | $0.44 | 19.86% | 110.61% | $43.75 |
|
AMRN
Amarin Corp. Plc
|
$50.6M | $0.07 | 1.39% | -100% | $12.00 |
|
MDT
Medtronic Plc
|
$8.9B | $1.34 | 7.27% | 32.75% | $110.83 |
|
PRGO
Perrigo Co. Plc
|
$1.1B | $0.79 | 1.55% | 5557.8% | $21.00 |
|
ZYME
Zymeworks, Inc.
|
$19.5M | -$0.32 | -10.72% | -68.68% | $35.62 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
$167.29 | $216.44 | $10.2B | 15.09x | $0.00 | 0% | 2.46x |
|
ALKS
Alkermes Plc
|
$34.96 | $43.75 | $5.8B | 17.30x | $0.00 | 0% | 3.86x |
|
AMRN
Amarin Corp. Plc
|
$14.81 | $12.00 | $307.9M | -- | $0.00 | 0% | 7.73x |
|
MDT
Medtronic Plc
|
$102.71 | $110.83 | $131.7B | 27.75x | $0.71 | 2.76% | 3.80x |
|
PRGO
Perrigo Co. Plc
|
$14.32 | $21.00 | $2B | -- | $0.29 | 8.1% | 0.46x |
|
ZYME
Zymeworks, Inc.
|
$23.17 | $35.62 | $1.7B | -- | $0.00 | 0% | 13.05x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.201 | 67.81% | 1.24x |
|
ALKS
Alkermes Plc
|
3.97% | 0.553 | 1.45% | 3.09x |
|
AMRN
Amarin Corp. Plc
|
1.45% | 2.913 | 1.98% | 2.35x |
|
MDT
Medtronic Plc
|
37.43% | 0.302 | 24.98% | 1.50x |
|
PRGO
Perrigo Co. Plc
|
46.25% | 0.161 | 124.88% | 0.97x |
|
ZYME
Zymeworks, Inc.
|
5.58% | 0.686 | 1.46% | 6.69x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
|
ALKS
Alkermes Plc
|
$341.2M | $89.1M | 20.4% | 22.16% | 22.6% | $84.4M |
|
AMRN
Amarin Corp. Plc
|
$21.2M | -$1.7M | -17.51% | -17.79% | -3.42% | -$12.8M |
|
MDT
Medtronic Plc
|
$5.4B | $1.7B | 6.21% | 9.84% | 19.31% | $457M |
|
PRGO
Perrigo Co. Plc
|
$377.5M | $106.9M | -0.34% | -0.66% | 10.25% | $29.8M |
|
ZYME
Zymeworks, Inc.
|
$25M | -$22.1M | -17.82% | -18.82% | -80.07% | -$32.3M |
Jazz Pharmaceuticals Plc vs. Competitors
-
Which has Higher Returns JAZZ or ALKS?
Alkermes Plc has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of 21%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Alkermes Plc's return on equity of 22.16%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B ALKSAlkermes Plc86.56% $0.49 $1.8B -
What do Analysts Say About JAZZ or ALKS?
Jazz Pharmaceuticals Plc has a consensus price target of $216.44, signalling upside risk potential of 29.94%. On the other hand Alkermes Plc has an analysts' consensus of $43.75 which suggests that it could grow by 25.14%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Alkermes Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Alkermes Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc10 1 0 ALKSAlkermes Plc11 3 0 -
Is JAZZ or ALKS More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.260, which suggesting that the stock is 73.986% less volatile than S&P 500. In comparison Alkermes Plc has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.612%.
-
Which is a Better Dividend Stock JAZZ or ALKS?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alkermes Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Alkermes Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or ALKS?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are larger than Alkermes Plc quarterly revenues of $394.2M. Jazz Pharmaceuticals Plc's net income of $251.4M is higher than Alkermes Plc's net income of $82.8M. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Alkermes Plc's PE ratio is 17.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.46x versus 3.86x for Alkermes Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.46x 15.09x $1.1B $251.4M ALKSAlkermes Plc3.86x 17.30x $394.2M $82.8M
-
Which has Higher Returns JAZZ or AMRN?
Amarin Corp. Plc has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of -15.58%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Amarin Corp. Plc's return on equity of -17.79%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M -
What do Analysts Say About JAZZ or AMRN?
Jazz Pharmaceuticals Plc has a consensus price target of $216.44, signalling upside risk potential of 29.94%. On the other hand Amarin Corp. Plc has an analysts' consensus of $12.00 which suggests that it could fall by -18.97%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Amarin Corp. Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc10 1 0 AMRNAmarin Corp. Plc0 1 1 -
Is JAZZ or AMRN More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.260, which suggesting that the stock is 73.986% less volatile than S&P 500. In comparison Amarin Corp. Plc has a beta of 0.839, suggesting its less volatile than the S&P 500 by 16.124%.
-
Which is a Better Dividend Stock JAZZ or AMRN?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Amarin Corp. Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or AMRN?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are larger than Amarin Corp. Plc quarterly revenues of $49.4M. Jazz Pharmaceuticals Plc's net income of $251.4M is higher than Amarin Corp. Plc's net income of -$7.7M. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Amarin Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.46x versus 7.73x for Amarin Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.46x 15.09x $1.1B $251.4M AMRNAmarin Corp. Plc7.73x -- $49.4M -$7.7M
-
Which has Higher Returns JAZZ or MDT?
Medtronic Plc has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of 15.42%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Medtronic Plc's return on equity of 9.84%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B MDTMedtronic Plc60.45% $1.07 $78B -
What do Analysts Say About JAZZ or MDT?
Jazz Pharmaceuticals Plc has a consensus price target of $216.44, signalling upside risk potential of 29.94%. On the other hand Medtronic Plc has an analysts' consensus of $110.83 which suggests that it could grow by 7.91%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Medtronic Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Medtronic Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc10 1 0 MDTMedtronic Plc13 14 0 -
Is JAZZ or MDT More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.260, which suggesting that the stock is 73.986% less volatile than S&P 500. In comparison Medtronic Plc has a beta of 0.709, suggesting its less volatile than the S&P 500 by 29.108%.
-
Which is a Better Dividend Stock JAZZ or MDT?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic Plc offers a yield of 2.76% to investors and pays a quarterly dividend of $0.71 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Medtronic Plc pays out 77.47% of its earnings as a dividend. Medtronic Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JAZZ or MDT?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are smaller than Medtronic Plc quarterly revenues of $9B. Jazz Pharmaceuticals Plc's net income of $251.4M is lower than Medtronic Plc's net income of $1.4B. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Medtronic Plc's PE ratio is 27.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.46x versus 3.80x for Medtronic Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.46x 15.09x $1.1B $251.4M MDTMedtronic Plc3.80x 27.75x $9B $1.4B
-
Which has Higher Returns JAZZ or PRGO?
Perrigo Co. Plc has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of 1.22%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Perrigo Co. Plc's return on equity of -0.66%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B PRGOPerrigo Co. Plc36.19% $0.05 $8.3B -
What do Analysts Say About JAZZ or PRGO?
Jazz Pharmaceuticals Plc has a consensus price target of $216.44, signalling upside risk potential of 29.94%. On the other hand Perrigo Co. Plc has an analysts' consensus of $21.00 which suggests that it could grow by 46.65%. Given that Perrigo Co. Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Perrigo Co. Plc is more attractive than Jazz Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc10 1 0 PRGOPerrigo Co. Plc2 3 0 -
Is JAZZ or PRGO More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.260, which suggesting that the stock is 73.986% less volatile than S&P 500. In comparison Perrigo Co. Plc has a beta of 0.391, suggesting its less volatile than the S&P 500 by 60.882%.
-
Which is a Better Dividend Stock JAZZ or PRGO?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co. Plc offers a yield of 8.1% to investors and pays a quarterly dividend of $0.29 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Perrigo Co. Plc pays out 94.9% of its earnings as a dividend. Perrigo Co. Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JAZZ or PRGO?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are larger than Perrigo Co. Plc quarterly revenues of $1B. Jazz Pharmaceuticals Plc's net income of $251.4M is higher than Perrigo Co. Plc's net income of $12.7M. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Perrigo Co. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.46x versus 0.46x for Perrigo Co. Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.46x 15.09x $1.1B $251.4M PRGOPerrigo Co. Plc0.46x -- $1B $12.7M
-
Which has Higher Returns JAZZ or ZYME?
Zymeworks, Inc. has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of -70.99%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Zymeworks, Inc.'s return on equity of -18.82%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B ZYMEZymeworks, Inc.90.64% -$0.26 $339M -
What do Analysts Say About JAZZ or ZYME?
Jazz Pharmaceuticals Plc has a consensus price target of $216.44, signalling upside risk potential of 29.94%. On the other hand Zymeworks, Inc. has an analysts' consensus of $35.62 which suggests that it could grow by 53.71%. Given that Zymeworks, Inc. has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Zymeworks, Inc. is more attractive than Jazz Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc10 1 0 ZYMEZymeworks, Inc.12 0 0 -
Is JAZZ or ZYME More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.260, which suggesting that the stock is 73.986% less volatile than S&P 500. In comparison Zymeworks, Inc. has a beta of 1.245, suggesting its more volatile than the S&P 500 by 24.531%.
-
Which is a Better Dividend Stock JAZZ or ZYME?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Zymeworks, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or ZYME?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are larger than Zymeworks, Inc. quarterly revenues of $27.6M. Jazz Pharmaceuticals Plc's net income of $251.4M is higher than Zymeworks, Inc.'s net income of -$19.6M. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Zymeworks, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.46x versus 13.05x for Zymeworks, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.46x 15.09x $1.1B $251.4M ZYMEZymeworks, Inc.13.05x -- $27.6M -$19.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 43x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 43x
Alerts
Sell
49
HYMC alert for Feb 3
Hycroft Mining Holding Corp. [HYMC] is up 19.68% over the past day.
Buy
67
FBRX alert for Feb 3
Forte Biosciences, Inc. [FBRX] is down 0.2% over the past day.
Buy
72
BNR alert for Feb 3
Burning Rock Biotech Ltd. [BNR] is down 15.43% over the past day.
